Co announces that they have licensed their antibody phage display libraries to Cambridge Antibody Technology, a wholly-owned subsidiary of AstraZeneca (AZN), for the discovery of therapeutic ...

When a pathogen infects a healthy host, the host’s immune system responds to fight it off and maintain health. The host produces antibodies that recognize the antigens present on the surface of the ...

Clinical drug candidates must have not only appropriate affinity and target specificity, but also optimal biophysical properties. Using nuclease-directed integration, we constructed large mammalian ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

-- Rapid, Function-Forward mAb Discovery against a Cell Surface Target via Concurrent Use of Humanized and Hyperimmune Mice Presentation on May 4 -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist ...

At a recent CHI meeting in Cambridge, MA, “Recombinant Antibodies from Concept to Clinic”, a wide range of new antibody technologies were covered. Dana Ault-Rich, Ph.D., CEO of Pointilliste (Mountain ...

GlobalBio’s validated, highly diverse human antibody libraries are now available pre-integrated into Neochromosome’s novel neoSwitch™ yeast strain, enabling rapid in-house antibody discovery via yeast ...

The official launch of the OptiMAL platform took place at the Antibody Engineering and Therapeutics conference in San Diego with a speaker presentation by Dr Richard Buick, CSO, followed by poster ...

Membrane proteins are important therapeutic targets as they transduce signals into cells, transport molecules, bind to surfaces, and catalyze reactions. However, researchers face challenges when ...

Vaishali Verma (left) is an Assistant Professor in the Department of Biotechnology at Bennett University (Uttar Pradesh, India) who develops immunochemical reagents for the diagnosis of drug-resistant ...